Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA) : long-term survival results from the randomized phase 3 PHILA trial

This database derives from the multicentre, double-blind, randomised, open label phase 3 PHILA trial evaluating pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. The shared database includes patient level analysis datasets (ADSL, ADTTE, ADAE, ADCM, ADSLRS, ADEX), covering anonymised subject identifiers, demographics, baseline disease characteristics, treatment allocation and exposure, tumour response assessments, time-to-event outcomes, adverse events, medical history, concomitant medications and follow-up anti-cancer therapies.